Impact of prior cancer history on the survival of patients with larynx cancer

Patients with a prior history of cancer are commonly excluded from clinical trial. Increasing number of studies implied that a prior cancer did not adversely affect the clinical outcome among various types of cancer patients. However, the impact of prior cancer on survival of larynx cancer patients...

Full description

Saved in:
Bibliographic Details
Published in:BMC cancer 2020-11, Vol.20 (1), p.1137-1137, Article 1137
Main Authors: Zhu, Kaiquan, Lin, Renyu, Zhang, Ziheng, Chen, Huanqi, Rao, Xingwang
Format: Article
Language:English
Subjects:
Breast
Bronchus
Cancer
Care and treatment
Chemotherapy
Clinical outcomes
Clinical trials
Colorectal cancer
Diagnosis
Epidemiology
Evaluation
Female
Heredity
Humans
Laryngeal cancer
Laryngeal Neoplasms - genetics
Laryngeal Neoplasms - mortality
Larynx
Lung cancer
Male
Malignancy
Medical diagnosis
Medical prognosis
Middle Aged
Oncology, Experimental
Prognosis
Prostate
Prostate cancer
Radiation therapy
Risk factors
Software
Survival
Survival Analysis
Urinary bladder
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Patients with a prior history of cancer are commonly excluded from clinical trial. Increasing number of studies implied that a prior cancer did not adversely affect the clinical outcome among various types of cancer patients. However, the impact of prior cancer on survival of larynx cancer patients remains largely unknown. The aim of this study was to evaluate the prevalence of prior cancer and assess its impact on survival of patients diagnosed with larynx cancer. Patients with larynx cancer as the first or second primary malignancy diagnosed from 2004 to 2015 were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. Propensity score matching (PSM) was conducted to balance baseline characteristics. Kaplan-Meier method, multivariate Cox proportional hazard model, and multivariate competing risk model were performed for survival analysis. A total of 24,812 eligible patients with larynx cancer were included in the study, wherein a total of 2436 patients (9.8%) had a prior history of cancer. Prostate (36%), lung and bronchus (10%), urinary bladder (7%), and breast (6%) were the most common types of prior cancer. A prior cancer history served as a risk factor for overall survival (AHR =1.30; 95% CI [1.21-1.41]; P 
ISSN:1471-2407
1471-2407
DOI:10.1186/s12885-020-07634-2